TY  - DBASE
TI  - Trial to investigate if the addition of two novel immunotherapy agents in combination with a chemotherapy agent can reduce the size of the cancer and how long they can delay the growth of the cancer in patients with metastatic pancreatic cancer.
DO  - https://dx.doi.org/10.1186/ISRCTN53212600
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Ongoing. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): Metastatic pancreatic cancer. 
INTERVENTION(S): Biological/Vaccine: Gemcitabine, pembrolizumab (MK-3475) and IMM-101. 
PHASE: Phase II. 
EST PARTICIPANTS: 50. 
FINAL ENROLMENT: NA. 
COUNTRY: United Kingdom; England; Scotland. 
TRIAL END DATE: 01/12/2026.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN53212600
ER  - 

TY  - DBASE
TI  - Understanding the usefulness of the PEAR-BIO platform in patients with kidney cancer
DO  - https://dx.doi.org/10.1186/ISRCTN10001405
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Completed. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Observational. 
CONDITION(S): Patients undergoing surgery for renal cell carcinoma. 
INTERVENTION(S): Device: Ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, lenvatinib, pazopanib, sunitinib, sorafenib, everolimus, sapanisertib. 
PHASE: Not Applicable. 
EST PARTICIPANTS: 20. 
FINAL ENROLMENT: NA. 
COUNTRY: United Kingdom; England. 
TRIAL END DATE: 31/03/2023.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN10001405
ER  - 

TY  - DBASE
TI  - LION: lifting immune checkpoints with NSAIDs
DO  - https://dx.doi.org/10.1186/ISRCTN73037722
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Ongoing. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): Triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC). 
INTERVENTION(S): Drug: Celecoxib, atezolizumab, nab-paclitaxel, pembrolizumab, nivolumab, ipilimumab. 
PHASE: Phase II. 
EST PARTICIPANTS: 89. 
FINAL ENROLMENT: NA. 
COUNTRY: United Kingdom; England. 
TRIAL END DATE: 03/06/2026.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN73037722
ER  - 

TY  - DBASE
TI  - Study of DS-1062a with or without pembrolizumab in advanced or metastatic non-small cell lung cancer
DO  - https://dx.doi.org/10.1186/ISRCTN24189848
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Ongoing. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): Advanced or metastatic non-small cell lung cancer (NSCLC). 
INTERVENTION(S): Drug: Datopotamab deruxtecan, pembrolizumab. 
PHASE: Phase III. 
EST PARTICIPANTS: 740. 
FINAL ENROLMENT: NA. 
COUNTRY: Argentina; Australia; Belgium; Brazil; Canada; Chile; China; France; Germany; Greece; Hong Kong; Hungary; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Russian Federation; Spain; Switzerland; Taiwan; Thailand; Turkey; Ukraine; United Kingdom; England; Scotland. 
TRIAL END DATE: 31/05/2025.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN24189848
ER  - 

TY  - DBASE
TI  - Pembrolizumab plus chemotherapy for diffuse large B-cell lymphoma that has come back or does not respond to treatment
DO  - https://dx.doi.org/10.1186/ISRCTN86607306
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Ongoing. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): Relapsed/refractory diffuse large B-cell lymphoma. 
INTERVENTION(S): Drug: Pembrolizumab, rituximab, ifosfamide, carboplatin, etoposide. 
PHASE: Phase II. 
EST PARTICIPANTS: 65. 
FINAL ENROLMENT: NA. 
COUNTRY: United Kingdom; England. 
TRIAL END DATE: 31/12/2026.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN86607306
ER  - 

TY  - DBASE
TI  - A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
DO  - https://dx.doi.org/10.1186/ISRCTN63646763
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Ongoing. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): Recurrent or metastatic squamous cell carcinoma of the head and neck. 
INTERVENTION(S): Drug: Setanaxib, pembrolizumb. 
PHASE: Phase II. 
EST PARTICIPANTS: 60. 
FINAL ENROLMENT: NA. 
COUNTRY: France; Germany; Italy; Poland; Spain; United Kingdom; England; United States of America. 
TRIAL END DATE: 30/06/2024.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN63646763
ER  - 

TY  - DBASE
TI  - A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
DO  - https://dx.doi.org/10.1186/ISRCTN11595117
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Ongoing. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): PIK3CA-mutated solid cancers including previously treated recurrent or metastatic HNSCC. 
INTERVENTION(S): Drug: Inavolisib, atezolizumab. 
PHASE: Phase I. 
EST PARTICIPANTS: 40. 
FINAL ENROLMENT: NA. 
COUNTRY: Canada; France; Spain; United Kingdom; United States of America. 
TRIAL END DATE: 01/04/2025.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN11595117
ER  - 

TY  - DBASE
TI  - Testing IMM60 in combination with pembrolizumab in melanoma and non-small cell lung cancer
DO  - https://dx.doi.org/10.1186/ISRCTN80472712
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Ongoing. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): Malignant neoplasms of respiratory and intrathoracic organs, Melanoma and other malignant neoplasms of skin. 
INTERVENTION(S): Drug: IMM60, pembrolizumab. 
PHASE: Phase I. 
EST PARTICIPANTS: 12. 
FINAL ENROLMENT: NA. 
COUNTRY: United Kingdom; England. 
TRIAL END DATE: 31/12/2023.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN80472712
ER  - 

TY  - DBASE
TI  - A trial to see the effect of cyclophosphamide and pembrolizumab on cancer in the kidney that has spread further into the body
DO  - https://dx.doi.org/10.1186/ISRCTN95900287
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Ongoing. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): Metastatic renal cell carcinoma. 
INTERVENTION(S): Drug: Cyclophosphamide, pembrolizumab. 
PHASE: Phase I. 
EST PARTICIPANTS: 21. 
FINAL ENROLMENT: NA. 
COUNTRY: United Kingdom; England; Scotland. 
TRIAL END DATE: 28/04/2024.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN95900287
ER  - 

TY  - DBASE
TI  - DANTE: Duration of Anti-PD1 therapy for melanoma
DO  - https://dx.doi.org/10.1186/ISRCTN15837212
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Ongoing. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): Metastatic melanoma. 
INTERVENTION(S): Other. 
PHASE: Phase IV. 
EST PARTICIPANTS: 1208. 
FINAL ENROLMENT: NA. 
COUNTRY: United Kingdom; England; Northern Ireland; Scotland; Wales. 
TRIAL END DATE: 15/10/2024.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN15837212
ER  - 

TY  - DBASE
TI  - PARIS-Pembrolizumab in combination with radiotherapy in locally advanced non-small cell lung cancer (NSCLC)
DO  - https://dx.doi.org/10.1186/ISRCTN14634058
AB  - THIS IS A TRIALS REGISTY RECORD. 
STATUS: Stopped. This may not be reflective of the actual state of the trial. 
STUDY DESIGN: Interventional. 
CONDITION(S): Lung Cancer. 
INTERVENTION(S): Other. 
PHASE: Phase I. 
EST PARTICIPANTS: 25. 
FINAL ENROLMENT: NA. 
COUNTRY: England; United Kingdom. 
TRIAL END DATE: 31/12/2020.
JF  - ISRCTN
UR  - https://www.isrctn.com/ISRCTN14634058
ER  - 

